T1	PROC 46 60	Ensayo fase II
T2	PROC 639 663	consentimiento informado
#1	AnnotatorNotes T2	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T3	PROC 77 105	tratamiento de mantenimiento
#2	AnnotatorNotes T3	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T4	DISO 136 166	cáncer de próstata metastásico
T5	PROC 183 193	castración
#3	AnnotatorNotes T5	C0007344; Castration; Therapeutic or Preventive Procedure
T6	DISO 253 263	enfermedad
#4	AnnotatorNotes T6	C0012634; Disease; Disease or Syndrome
T7	PROC 283 294	tratamiento
#5	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	DISO 332 362	Cáncer de próstata metastásico
T9	DISO 389 419	Cáncer de próstata metastásico
T10	PROC 436 446	castración
#6	AnnotatorNotes T10	C0007344; Castration; Therapeutic or Preventive Procedure
T11	PROC 489 513	consentimiento informado
#7	AnnotatorNotes T11	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T12	PROC 533 546	procedimiento
#8	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T13	PROC 680 702	investigación genética
T14	PROC 724 746	asesoramiento genético
#9	AnnotatorNotes T14	C0017382; Genetic Counseling; Therapeutic or Preventive Procedure
T15	DISO 913 939	Adenocarcinoma de próstata
#10	AnnotatorNotes T15	C0007112; Adenocarcinoma of prostate; Neoplastic Process
T16	DISO 766 774	mutación
T17	DISO 998 1020	enfermedad metastásica
#11	AnnotatorNotes T17	C2939420; Metastatic Neoplasm; Neoplastic Process
T18	PROC 1042 1053	tratamiento
#12	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	DISO 1069 1091	enfermedad metastásica
#13	AnnotatorNotes T19	C2939420; Metastatic Neoplasm; Neoplastic Process
T20	PROC 1108 1124	exploración ósea
T21	DISO 1136 1157	lesiones metastásicas
T22	PROC 1168 1170	RM
#14	AnnotatorNotes T22	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T23	CHEM 1203 1210	platino
#15	AnnotatorNotes T23	C0032207; platinum; Element, Ion, or Isotope
T24	CHEM 1212 1226	ciclofosfamida
#16	AnnotatorNotes T24	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T25	CHEM 1228 1240	mitoxantrona
#17	AnnotatorNotes T25	C0026259; mitoxantrone; Organic Chemical · Pharmacologic Substance
T26	CHEM 1243 1262	inhibidores de PARP
#18	AnnotatorNotes T26	C4319819; Substance with polyadenosine 5'-diphosphoribose polymerase inhibitor mechanism of action (substance); Pharmacologic Substance
T27	PROC 1512 1527	estudio clínico
#19	AnnotatorNotes T27	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T28	CHEM 1622 1639	inhibidor de PARP
#20	AnnotatorNotes T28	C4319819; Substance with polyadenosine 5'-diphosphoribose polymerase inhibitor mechanism of action (substance); Pharmacologic Substance
T29	PROC 1599 1610	tratamiento
#21	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	CHEM 1652 1660	olaparib
#22	AnnotatorNotes T30	C2316164; olaparib; Organic Chemical · Pharmacologic Substance
T31	DISO 1689 1699	mutaciones
#23	AnnotatorNotes T31	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T32	DISO 2059 2075	tumores malignos
#24	AnnotatorNotes T32	C0006826; Malignant Neoplasms; Neoplastic Process
T33	DISO 2107 2133	cáncer de piel no melanoma
#25	AnnotatorNotes T33	C0699893; Skin carcinoma; Neoplastic Process
T34	DISO 2157 2189	cáncer de cuello uterino in situ
T35	DISO 2217 2221	DCIS
#26	AnnotatorNotes T35	C1302731; Ductal carcinoma in situ; Neoplastic Process
T36	DISO 2191 2215	carcinoma ductal in situ
#27	AnnotatorNotes T36	C0007124; Noninfiltrating Intraductal Carcinoma; Neoplastic Process
T37	DISO 2224 2247	carcinoma de endometrio
T39	PROC 2134 2141	tratado
#28	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T40	DISO 2305 2313	linfomas
#29	AnnotatorNotes T40	C0024299; Lymphoma; Neoplastic Process
T41	CHEM 110 118	olaparib
#30	AnnotatorNotes T41	C2316164; olaparib; Organic Chemical · Pharmacologic Substance
T42	ANAT 146 154	próstata
#31	AnnotatorNotes T42	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T43	CHEM 299 308	docetaxel
#32	AnnotatorNotes T43	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T44	ANAT 342 350	próstata
#33	AnnotatorNotes T44	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T45	ANAT 399 407	próstata
#34	AnnotatorNotes T45	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T46	ANAT 931 939	próstata
#35	AnnotatorNotes T46	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T47	CHEM 1058 1067	docetaxel
#36	AnnotatorNotes T47	C0246415; docetaxel; Organic Chemical · Pharmacologic Substance
T48	ANAT 1120 1124	ósea
#37	AnnotatorNotes T48	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T49	PROC 1164 1166	TC
#38	AnnotatorNotes T49	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T50	DISO 1787 1797	mutaciones
#39	AnnotatorNotes T50	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
T51	ANAT 2117 2121	piel
#40	AnnotatorNotes T51	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T52	ANAT 2167 2181	cuello uterino
#41	AnnotatorNotes T52	C0007874; Cervix Uteri; Body Part, Organ, or Organ Component | C1278987; Entire cervix uteri; Body Part, Organ, or Organ Component
T53	ANAT 2201 2207	ductal
#42	AnnotatorNotes T53	C0687028; Duct (organ) structure; Body Part, Organ, or Organ Component
T54	ANAT 2237 2247	endometrio
#43	AnnotatorNotes T54	C0014180; Endometrium; Body Part, Organ, or Organ Component | C1269566; Entire endometrium; Body Part, Organ, or Organ Component
T55	Date 13 17	2017
T56	LIVB 122 131	pacientes
#44	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 607 616	pacientes
#45	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	GENE 694 702	genética
#46	AnnotatorNotes T58	C0017337; Genes; Gene or Genome
T59	LIVB 752 761	pacientes
#47	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	GENE 814 851	genes Homologous Recombination Repair
#48	AnnotatorNotes T60	C4727118; Homologous Recombination Repair Gene; Gene or Genome
T61	LIVB 856 873	Pacientes varones
#49	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group
T62	Age 891 900	≥ 18 años
T63	LIVB 976 985	pacientes
#50	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Neg_cue 1176 1178	No
T66	Date 1569 1582	el último mes
T67	LIVB 1665 1674	Pacientes
#51	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	Neg_cue 1679 1681	no
T69	Spec_cue 1716 1730	sospechosas de
T70	GENE 1731 1768	genes Homologous Recombination Repair
#52	AnnotatorNotes T70	C4727118; Homologous Recombination Repair Gene; Gene or Genome
T71	GENE 1805 1846	genes de reparación recombinante homóloga
#53	AnnotatorNotes T71	C4727118; Homologous Recombination Repair Gene; Gene or Genome
T74	PHYS 1993 2005	polimorfismo
#54	AnnotatorNotes T74	C0032529; Genetic Polymorphism; Genetic Function
T75	PHYS 2020 2032	polimorfismo
#55	AnnotatorNotes T75	C0032529; Genetic Polymorphism; Genetic Function
T76	Duration 2079 2097	los últimos 5 años
T77	Neg_cue 2098 2105	excepto
T80	GENE 738 746	genético
#56	AnnotatorNotes T80	C0017337; Genes; Gene or Genome
T38	DISO 2278 2293	tumores sólidos
#57	AnnotatorNotes T38	C0280100; Solid Neoplasm; Neoplastic Process
T72	PHYS 766 792	mutación de línea germinal
#58	AnnotatorNotes T72	C0206530; Germ-Line Mutation; Genetic Function
T78	LIVB 1394 1402	personal
#59	AnnotatorNotes T78	C0851286; Staff; Professional or Occupational Group
T79	LIVB 1409 1417	personal
#60	AnnotatorNotes T79	C0851286; Staff; Professional or Occupational Group
T65	CHEM 1535 1560	producto de investigación
#61	AnnotatorNotes T65	C0013230; Investigational New Drugs; Pharmacologic Substance
T73	PROC 940 956	histológicamente
#62	AnnotatorNotes T73	C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T23 Negated
A2	Assertion T24 Negated
A3	Assertion T25 Negated
A4	Assertion T26 Negated
A5	Assertion T31 Negated
A6	Assertion T70 Speculated
A8	Assertion T33 Negated
A9	Assertion T34 Negated
A10	Assertion T36 Negated
A11	Assertion T37 Negated
A7	Assertion T35 Negated
A12	Assertion T38 Negated
A13	Assertion T40 Negated
A14	Status T23 History_of
A15	Status T24 History_of
A16	Status T25 History_of
A17	Status T26 History_of
A18	Status T29 History_of
A19	Status T28 History_of
A20	Status T30 History_of
#63	AnnotatorNotes T1	C0282460; Phase 2 Clinical Trials; Research Activity
#64	AnnotatorNotes T4	C0936223; Metastatic Prostate Carcinoma; Neoplastic Process
#65	AnnotatorNotes T8	C0936223; Metastatic Prostate Carcinoma; Neoplastic Process
#66	AnnotatorNotes T9	C0936223; Metastatic Prostate Carcinoma; Neoplastic Process
#67	AnnotatorNotes T13	C0243064; Genetic Research; Research Activity 
#68	AnnotatorNotes T16	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#69	AnnotatorNotes T20	C0185155; Exploration of bone; Diagnostic Procedure 
#70	AnnotatorNotes T37	C0476089; Endometrial Carcinoma; Neoplastic Process 
T81	Quantifier_or_Qualifier 1868 1881	perjudiciales
A21	Assertion T81 Negated
T82	Neg_cue 1865 1867	no
T83	Observation 1910 1929	significado clínico
A22	Assertion T83 Speculated
#71	AnnotatorNotes T83	C2826293; Clinical Significance; Finding
T84	Spec_cue 1930 1938	incierto
T85	Observation 1955 1966	significado
A23	Assertion T85 Speculated
#72	AnnotatorNotes T85	C2826293; Clinical Significance; Finding
T86	Spec_cue 1967 1978	desconocido
R1	Speculation Arg1:T86 Arg2:T85	
R2	Speculation Arg1:T84 Arg2:T83	
R3	Negation Arg1:T64 Arg2:T23	
R4	Negation Arg1:T64 Arg2:T24	
R5	Negation Arg1:T64 Arg2:T25	
R6	Negation Arg1:T64 Arg2:T26	
R7	Negation Arg1:T68 Arg2:T31	
T87	Quantifier_or_Qualifier 1700 1713	perjudiciales
A24	Assertion T87 Negated
R8	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T87	
R9	Negation Arg1:T68 Arg2:T87	
R10	Speculation Arg1:T69 Arg2:T70	
R11	Negation Arg1:T82 Arg2:T81	
R12	Negation Arg1:T77 Arg2:T33	
R13	Used_for Arg1:T41 Arg2:T3	
R14	Experiences Arg1:T56 Arg2:T3	
R15	Experiences Arg1:T56 Arg2:T4	
R16	Location_of Arg1:T42 Arg2:T4	
R17	Experiences Arg1:T56 Arg2:T5	
T88	Observation 167 193	resistente a la castración
#73	AnnotatorNotes T88	C4329620; Castration Resistance; Finding
R18	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T88	
T89	Observation 233 250	respuesta parcial
#74	AnnotatorNotes T89	C1521726; partial response; Finding
R20	After Arg1:T88 Arg2:T89	
R21	Overlap Arg1:T43 Arg2:T7	
T90	Quantifier_or_Qualifier 264 271	estable
#75	AnnotatorNotes T90	C0205360; Stable status; Qualitative Concept
R22	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T90	
R23	Overlap Arg1:T90 Arg2:T7	
R24	Experiences Arg1:T56 Arg2:T89	
R25	Experiences Arg1:T56 Arg2:T6	
R26	Location_of Arg1:T44 Arg2:T8	
R27	Location_of Arg1:T45 Arg2:T9	
T91	Observation 420 446	resistente a la castración
#76	AnnotatorNotes T91	C4329620; Castration Resistance; Finding
R28	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T91	
R29	Before Arg1:T11 Arg2:T12	
T92	CONC 579 588	inclusión
#77	AnnotatorNotes T92	C1512693; Inclusion; Qualitative Concept
R30	Before Arg1:T2 Arg2:T92	
R31	Before Arg1:T2 Arg2:T13	
R32	Experiences Arg1:T57 Arg2:T13	
R33	Experiences Arg1:T59 Arg2:T14	
R34	Experiences Arg1:T59 Arg2:T16	
R35	Experiences Arg1:T59 Arg2:T72	
R36	Location_of Arg1:T60 Arg2:T16	
R37	Has_Age Arg1:T61 Arg2:T62	
R38	Location_of Arg1:T46 Arg2:T15	
R40	Experiences Arg1:T63 Arg2:T17	
R41	Before Arg1:T17 Arg2:T18	
R42	Used_for Arg1:T47 Arg2:T18	
R43	Experiences Arg1:T63 Arg2:T19	
R45	Location_of Arg1:T48 Arg2:T20	
R46	Experiences Arg1:T63 Arg2:T18	
R48	Experiences Arg1:T63 Arg2:T21	
#78	AnnotatorNotes T21	C1513183; Metastatic Lesion; Finding
R51	Causes Arg1:T19 Arg2:T21	
T93	Result_or_Value 1125 1133	positiva
#79	AnnotatorNotes T93	C1446409; Positive; Finding
R52	Has_Result_or_Value Arg1:T20 Arg2:T93	
T94	Observation 1293 1356	Participación en la planificación y / o realización del estudio
T95	CONC 1446 1455	Inclusión
A25	Status T95 History_of
#80	AnnotatorNotes T95	C1512693; Inclusion; Qualitative Concept
T96	Observation 1490 1527	Participación en otro estudio clínico
R54	Overlap Arg1:T65 Arg2:T66	
R55	Overlap Arg1:T96 Arg2:T66	
R56	Used_for Arg1:T28 Arg2:T29	
R57	Used_for Arg1:T30 Arg2:T29	
R58	Experiences Arg1:T67 Arg2:T31	
R59	Location_of Arg1:T70 Arg2:T31	
R60	Experiences Arg1:T67 Arg2:T50	
R61	Location_of Arg1:T71 Arg2:T50	
R62	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T81	
T97	Quantifier_or_Qualifier 2006 2015	favorable
#81	AnnotatorNotes T97	C3640814; Favorable; Qualitative Concept
R63	Has_Quantifier_or_Qualifier Arg1:T74 Arg2:T97	
T98	Quantifier_or_Qualifier 2033 2040	benigno
#82	AnnotatorNotes T98	C0205183; Benign; Qualitative Concept
R64	Has_Quantifier_or_Qualifier Arg1:T75 Arg2:T98	
R65	Experiences Arg1:T67 Arg2:T74	
R66	Experiences Arg1:T67 Arg2:T75	
R67	Overlap Arg1:T32 Arg2:T76	
R68	Location_of Arg1:T51 Arg2:T33	
R69	Location_of Arg1:T52 Arg2:T34	
R70	Location_of Arg1:T53 Arg2:T36	
R71	Location_of Arg1:T54 Arg2:T37	
R72	Negation Arg1:T77 Arg2:T34	
T99	Quantifier_or_Qualifier 2142 2155	adecuadamente
R73	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T99	
#83	AnnotatorNotes T99	C0205411; Adequate; Qualitative Concept
R74	Location_of Arg1:T53 Arg2:T35	
R75	Negation Arg1:T77 Arg2:T36	
R76	Negation Arg1:T77 Arg2:T35	
R77	Negation Arg1:T77 Arg2:T37	
T100	Quantifier_or_Qualifier 2251 2258	grado 1
R78	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T100	
A26	Assertion T100 Negated
R79	Negation Arg1:T77 Arg2:T100	
T101	Quantifier_or_Qualifier 2260 2269	estadio 1
A27	Assertion T101 Negated
R80	Negation Arg1:T77 Arg2:T101	
R81	Negation Arg1:T77 Arg2:T38	
R82	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T101	
R83	Negation Arg1:T77 Arg2:T40	
R84	Experiences Arg1:T56 Arg2:T7	
R85	Experiences Arg1:T63 Arg2:T49	
R86	Experiences Arg1:T63 Arg2:T22	
#84	AnnotatorNotes T34	C0851140; Carcinoma in situ of uterine cervix; Neoplastic Process (?) | C0346203; Cervical Adenocarcinoma In Situ; Neoplastic Process (?)
#85	AnnotatorNotes T100	C0444502; First degree; Qualitative Concept 
R19	Experiences Arg1:T56 Arg2:T88	
R39	Experiences Arg1:T63 Arg2:T20	
A28	Experiencer T56 Patient
A29	Experiencer T57 Patient
A30	Experiencer T59 Patient
A31	Experiencer T61 Patient
A32	Experiencer T63 Patient
A33	Experiencer T78 Other
A34	Experiencer T79 Other
A35	Experiencer T67 Patient
